Log in

NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, Forecast & News

+0.20 (+1.06 %)
(As of 02/27/2020 04:14 AM ET)
Today's Range
Now: $19.11
50-Day Range
MA: $18.70
52-Week Range
Now: $19.11
Volume246,910 shs
Average Volume217,463 shs
Market Capitalization$839.43 million
P/E RatioN/A
Dividend YieldN/A
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RYTM



Sales & Book Value

Annual SalesN/A
Book Value$7.16 per share


Net Income$-74,060,000.00


Market Cap$839.43 million
Next Earnings Date3/13/2020 (Estimated)

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its quarterly earnings results on Friday, November, 1st. The company reported ($1.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.02. View Rhythm Pharmaceuticals' Earnings History.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Rhythm Pharmaceuticals.

What price target have analysts set for RYTM?

6 analysts have issued 1 year price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $18.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' stock price to reach $35.33 in the next year. This suggests a possible upside of 84.9% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.

What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.

What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (1/9/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We’ve learned from management that the yield will be broken out by patient type. We continue to look for ~2,500 identified and diagnosed MC4R patients in the U.S., with roughly half of them being BBS patients (see Exhibit 4). While management has not provided its internal estimates, it has now stated the number of BBS/Alström patients has exceeded its expectations." (9/9/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and our $34 target price on RYTM shares after the company reported its 2Q19 financials and business update. As we highlighted in our recent upgrade note (here), at the current share price, we believe there is a favorable risk/reward ahead of the Phase 3 data readouts for setmelanotide in POMC and LEPR deficiency obesities which are expected in the coming weeks. We believe both Phase 3 studies will be positive and in our homerun" scenario the stock could move up to the low ~$40 range. Additionally, we believe the 4Q19 update from management on its ongoing patient identification efforts for POMC/LEPR and other MC4R pathway disorders remain an unappreciated catalyst investors should be tracking." (7/29/2019)

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

Headlines about RYTM stock have trended negative on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Rhythm Pharmaceuticals.

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 1,980,000 shares, a drop of 7.0% from the January 30th total of 2,130,000 shares. Based on an average trading volume of 262,300 shares, the days-to-cover ratio is currently 7.5 days. Currently, 6.0% of the shares of the stock are short sold. View Rhythm Pharmaceuticals' Current Options Chain.

Who are some of Rhythm Pharmaceuticals' key competitors?

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the folowing people:
  • Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
  • Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
  • Mr. Simon D. Kelner, Chief HR Officer (Age 46)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (12.34%), Janus Henderson Group PLC (9.80%), MPM Asset Management LLC (5.45%), FMR LLC (2.34%), State Street Corp (2.12%) and Geode Capital Management LLC (0.91%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan, Orbimed Advisors Llc and Todd Foley. View Institutional Ownership Trends for Rhythm Pharmaceuticals.

Which major investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, SG Americas Securities LLC, FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Rice Hall James & Associates LLC and Citigroup Inc.. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan and Todd Foley. View Insider Buying and Selling for Rhythm Pharmaceuticals.

Which major investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Janus Henderson Group PLC, State Street Corp, Perceptive Advisors LLC, Perceptive Advisors LLC, Barclays PLC, Geode Capital Management LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Rhythm Pharmaceuticals.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $19.11.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $839.43 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.View Additional Information About Rhythm Pharmaceuticals.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is http://www.rhythmtx.com/.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel